French cities launch community push to wipe out hepatitis c in drug users

NCT ID NCT05794646

Ongoing Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aims to eliminate hepatitis C among people who use drugs in Paris, Marseille, Lyon, and Fort-de-France. Researchers will screen participants, provide immediate treatment, and use a peer-referral system to reach more people. The goal is to see if this community-based approach can effectively cure hepatitis C and reduce its spread.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hepatitis C antiviral treatment
What this could lead to: If successful, this could show a practical way to eliminate hepatitis C in high-risk communities, reducing transmission and liver disease.
What could go wrong: This is an implementation study, not a drug trial, so it tests feasibility rather than a new cure. Success depends on community participation and follow-up, which may be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection Psychological Well-Being substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV SUBSTANCE USE DISORDERS

Contacts and locations

Locations

Lyon

Lyon, Auvergne-Rhône-Alpes, 69000, France
Marseille

Marseille, PACA, 13000, France
Martinique

Fort-de-France, Martinique, 97200, Martinique
Paris

Paris, Île-de-France Region, 75000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.